Armis Named a Leader in 2025 Gartner® Magic Quadrant™ for CPS Protection Platforms
18.2.2025 17:30:00 CET | Business Wire | Press release
Armis supports global enterprises’ vast and varied needs to effectively secure critical CPS environments
Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2025 Gartner Magic Quadrant for CPS Protection Platforms.
Cyber-physical system environments connect the physical and digital worlds, supporting sectors including infrastructure, transportation, healthcare and smart manufacturing. Their growing role increases risk due to complex IT, OT, IoT, and IIoT integrations that need robust security. We believe the Gartner Magic Quadrant for CPS Protection Platforms highlights the importance of protecting these systems.
“Attacks on cyber-physical systems can disrupt operations and endanger lives, making their security our core mission, driven by innovation, expertise and customer collaboration,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe being named a Leader in this report is a testament to the support that we provide and the partnerships that we have with our customers as part of our unwavering commitment to redefining and advancing the security of cyber-physical systems. We will continue to innovate to protect society as we know it from the attacks of cybercriminals and nation-state adversaries who aim to cause disruption and harm.”
Armis was named a Leader within this report among the 17 vendors that were evaluated. Armis Centrix™, the Armis Cyber Exposure Management Platform, was positioned within the report for its Completeness of Vision and Ability to Execute.
As of February 11, 2025, Armis had 28 reviews on Gartner Peer Insights™ in the CPS Protection Platform category with an overall rating of 4.7 out of 5. Read customers’ praises of Armis’ CPS Protection Platform solution through verified ratings and reviews on Gartner® Peer Insights here and below:
- “Support for this product is by far the best I've encountered out of any product I use here. The usefulness of this product is pivotal for visibility of devices on our network.” - Manager, IT Security and Risk Management (Industry: Manufacturing)
- “Armis provides the Cybersecurity team with what it needs seamlessly. It helps us manage our assets, identify and resolve vulnerabilities faster, and helps us make better decisions on our security policy. Our customer success manager has always made himself available to us, which is key in being able to understand Armis' capabilities and how it benefits our organization.” - Cybersecurity Administrator (Industry: Government)
- “The company does a phenomenal job at listening to our questions/concerns and implementing a solution. They are truly customer focused.” - IT Security & Risk Management Associate (Industry: Healthcare and Biotech)
- "We had a positive experience with the vendor. Their team was consistently professional, prepared, and responsive. They also had initiatives for different use cases that were off our list initially. They demonstrated a strong understanding of the solution and the industry. Overall, the service was reliable and met our expectations well.” - Manager, IT Security (Industry: Retail)
- “Great experience. We have added a ton of visibility in our environment.” - IT Security & Risk Management Associate (Industry: Healthcare and BioTech)
Read our blog to learn more about why Armis was named a Leader in the 2025 Gartner® Magic Quadrant for CPS Protection Platforms.
Find more information about Armis Centrix™, the cyber exposure management platform, here.
For additional analyst reports recognizing Armis, please visit our Analyst Relations webpage.
Gartner Disclaimer
Gartner, Magic Quadrant for CPS Protection Platforms, Katell Thielemann, Wam Voster, Ruggero Contu, 12 February 2025.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT and PEER INSIGHTS is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
About Armis
Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218934891/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom